Asia Pacific Pharmaceutical Blister Packaging Market Size (2024 - 2029)

Asia Pacific Pharmaceutical Blister Packaging Market Analysis

The Asia Pacific Pharmaceutical Blister Packaging Market size is estimated at USD 9.68 billion in 2024, and is expected to reach USD 13.16 billion by 2029, growing at a CAGR of 6.32% during the forecast period (2024-2029).

The increasing incidence of new diseases, growth in regulatory norms, focus on people's health management, customers being more informed, and the increase in OTC drugs boost the growth of the pharmaceutical blister packaging market in the region.

• Extended shelf life is essential for the pharmaceutical sector, considering consumers store their drugs in a temperature-variant atmosphere that can harm unprotected medicines. Products include capsules, tablets, and sterile products.
• The growing population in developing countries such as India, rising health awareness, and increasing life expectancy can be attributed to the market's growth. The number of chronic disease cases is surging rapidly. According to WHO, over 20% of the country's population suffers from at least one of the chronic diseases, such as cancer, heart ailments, respiratory diseases, and diabetes, that are estimated to cost USD 6.2 trillion during the period 2012-2030. To prevent economic burdens in the coming years, pharmaceutical companies are researching and developing medicines to drive market growth.
• In August 2023, Aptar CSP Technologies partnered strategically with Porton Pharmatech to bring Activ-Blister solutions to the Asia-Pacific (APAC) region. The move followed the commercialization and approval of Activ-Blister technology with two HIV medications. The partnership with Porton provided pharma developers in the APAC region access to a local development and manufacturing resource for leveraging Aptar CSP's Activ-Blister solutions to protect sensitive drugs. Such collaborations drive market growth.
• In the pharmaceutical industry, blister packaging offers various solutions, such as PVC, PCTFE, PVDC, and thermoform blisters for less sensitive products. However, the unfitness for heavy items and stringent regulations in developing countries are anticipated to restrain market growth.
• Nationwide lockdowns, government regulations, and the steady rise in the national disease rate during the pandemic had far-reaching financial impacts on the market, especially in the early stages. However, the demand for packaging increased as the disease raised the demand for pharmaceutical products and concerns about the virus's ability to survive on the packaging surface.

Asia Pacific Pharmaceutical Blister Packaging Industry Segmentation

The pharmaceutical sector requires blister packaging solutions that are insulated from external surroundings, highly protected, cost-effective, and easy to handle. Moreover, blisters' unit dosage feature reduces the risk of incorrect dosing. Storing and handling the blister pack is convenient for commercial and household purposes, as the chances of damage are minimal.

The Asia-Pacific pharmaceutical blister packaging is segmented by material (plastic, paper, and aluminum), technology (cold forming and thermoforming), and country (China, India, Japan, Australia and New Zealand, and the Rest of Asia-Pacific). The report offers market sizes and forecasts in terms of value (USD) for all the above segments.